Background. Although consensus exists that malaria in pregnancy (MiP) increases the risk of malaria in infancy, and eventually nonmalarial fevers (NMFs), there is a lack of conclusive evidence of benefits of MiP preventive strategies in infants.
Malaria in pregnancy (MiP) causes significant adverse health effects in both mothers and their newborn children and is estimated to account for between 75 000 and 200 000 infant deaths a year [1] . While maternal mortality is often associated with severe maternal anemia, infant deaths are due to complications during pregnancy, such as fetal growth restriction, fetal anemia, preterm deliveries, and congenital malaria [1] .
The hallmark of MiP due to Plasmodium falciparum is placental malaria (PM), characterized by sequestration of infected erythrocytes in intervillous spaces of the placenta through binding to chondroitin sulfate A on syncytiotrophoblast [2] . Increasing evidence from birth cohort studies has shown that PM is associated with increased susceptibility to malaria during infancy [3] [4] [5] [6] [7] [8] , probably due to the acquisition of immune tolerance to parasite antigens during in utero exposure. Likewise, the development of a tolerogenic environment as a result of PM might also be the cause for increased infant susceptibility to nonmalarial fevers (NMFs) [9] .
Intermittent preventive treatment with at least 3 full sulfadoxine-pyrimethamine (IPTp-SP) doses (administered at least 1 month apart), combined with the use of insecticide-treated nets (ITNs), is currently the recommended strategy for preventing MiP in most malaria-endemic countries, as it reduces the risk of PM at delivery, neonatal mortality, and infants' low birth weight (LBW) [10] . However, the effectiveness of this IPTp-SPbased intervention is threatened by the growing spread of parasites with increasing resistance to SP [11] . In this context, studies assessing the impact of novel antimalarial interventions during pregnancy, not only on pregnant women but also on their infants, are urgently needed as information to date is scarce and inconclusive [12, 13] .
A multicenter community-based screening and treatment of malaria in pregnancy: a cluster randomized trial (COSMIC) was recently conducted in 3 West African countries with high (Burkina Faso and Benin) and low (The Gambia) malaria transmission, to assess the protective efficacy of adding community-scheduled screening and treatment of malaria during pregnancy to standard IPTp-SP (CSST/IPTp-SP). The CSST extension strategy was implemented monthly by community health workers using rapid diagnostic tests (RDTs). The aim of the combined CSST/IPTp-SP strategy was to provide additional opportunities to detect and treat malaria infections during pregnancy and reduce the prevalence of PM [14] .
In this study, we have followed infants born to mothers at the Burkina Faso site in the COSMIC trial, with the aim to evaluate whether CSST/IPTp-SP compared to IPTp-SP alone was effective in protecting infants from malaria and NMFs during the first year of life.
MATERIALS AND METHODS

Study Site
The study was conducted in Nanoro, a rural area with high malaria transmission located in the central-west region of Burkina Faso. Malaria transmission occurs year-round and is highly seasonal. Transmission peaks between July and December overlapping with the rainy season (July-November). Plasmodium falciparum is the main species responsible for transmission, with a prevalence of 90%. The prevalence of peripheral and placental P. falciparum infections at delivery during the high-transmission season is estimated at 32% and 34%, respectively [15] . In 2015, approximately 7.4 million of clinical malaria cases and 32000 malaria-related deaths were recorded in Burkina Faso [16] . Among 91 154 clinical malaria episodes that occurred in Nanoro health district in 2016, approximately 55% were detected among infants <5 years of age [17] .
Study Design and Participants
This was an observational birth cohort study of infants born to women who participated in the COSMIC trial (NCT01941264), described in detail elsewhere [14] . In COSMIC, it was assumed that CSST/IPTp-SP strategy would decrease PM by 30%. Following this assumption, and considering the prevalence of malaria infection in a 12-month birth cohort study in Benin (35%) [4] , as at the time of recruitment there were no such data available in Burkina Faso, we assumed that the impact of the intervention will decrease P. falciparum infection during the first year of life by 30%, from 35% to 25%. With a 1:1 ratio to provide a power of at least 80% with 5% precision, the required sample size was estimated to 350 newborns in each study arm. To account for loss to follow-up and exclusion criteria at delivery, a total of 752 pregnant women from COSMIC (376 in each arm) were enrolled between March 2014 and June 2015 into the current study. Written informed consent was obtained from all mothers and ethical approval was obtained from the institutional ethics committees of Centre Muraz, Bobo Dioulasso, Burkina Faso (006-2014/CE-CM), the Institute of Tropical Medicine, Antwerp, Belgium (953/14), and University Hospital in Antwerp, Belgium (14/26/277).
Recruitment and Follow-up Procedures
Pregnant women participating in the COSMIC trial were invited to participate in the present study at any antenatal care visits, but the enrollment of mother-child pairs onto the study occurred at time of delivery. Exclusion criteria at time of delivery were maternal death, stillbirth, and presence of major congenital malformation, chronic diseases, or signs of cerebral asphyxia. Maternal peripheral blood was collected by finger-prick to prepare blood smears and blood spots on filter paper for subsequent malaria diagnosis. A tissue section was collected from the maternal side of the placenta and preserved into 10% neutral buffered formalin at 4°C for histological examination within the COSMIC trial. A drop of placental blood was also spotted on filter paper. Infants were followed for 12 months and malaria infections were detected actively and passively. Active case detection consisted of 4 cross-sectional surveys conducted at 3, 6, 9, and 12 months of age. For each survey, blood films and blood spots on filter papers were collected for examination by light microscopy (LM) and quantitative real-time polymerase chain reaction (qPCR), respectively. For passive clinical case detection, mothers were encouraged to bring their offspring to the health center if they displayed any signs of illness. Infants presenting with fever (axillary temperature ≥37.5°C) on examination or a history of fever in the previous 24 hours were screened for malaria infection using RDT (SD-Bioline Malaria Ag P.f, Standard Diagnostic, Korea) and, if positive, treated according to national guidelines. Malaria diagnosis was subsequently confirmed by LM and qPCR.
Laboratory Methods
LM readings were taken according to standard procedures by 2 independent experienced readers [18] . A third reader was consulted in cases of discrepancies. Dried blood spots on filter papers were used for DNA extraction (QIAamp 96 DNA blood kit, Qiagen, Germany) and P. falciparum detection and quantification by Pf-varATS qPCR using procedures described elsewhere [15] . The limit of detection of the PfvasATS qPCR was estimated at 0.1 parasite/µL and qPCR was used as reference malaria diagnostic test. Data on past history of malaria infections during pregnancy and histological examinations of placental tissue data were obtained from the COSMIC trial [14] .
Data Analysis and Definition of Terms
Data were double entered into the study databases (OpenClinica, community version or Excel, Microsoft Corporation) and analyzed with Stata 12.0 software (StataCorp). The baseline characteristics of mother-child pairs were compared between the study arms. Continuous data normally distributed and categorical variables were analyzed using the t test and the χ 2 test, respectively. Non-normally distributed data were described using median and interquartile range (IQR).
The risk of malaria and NMFs during the first year of life was analyzed using the following outcomes: time from birth to the first clinical malaria episode, incidence of clinical malaria episodes, parasite density, prevalence of P. falciparum infection, and incidence of NMFs. The main exposure was the MiP intervention (CSST/IPTp-SP or IPTp-SP). The effect of prenatal malaria exposure-defined as maternal peripheral and placental infections-on outcome was investigated in a separate analysis. Maternal age, gravidity, ITN usage by mothers, birth season, and newborn sex were considered as potential confounders. Twin infants were excluded from the analysis.
The effect of the interventions on time to first clinical malaria episode was analyzed using Cox proportional univariate and multivariate analyses, while Kaplan-Meier analysis was used to calculate the survival curves. Because MiP preventive strategies may have a causal effect on pregnancy outcomes and subsequently an effect on the risk of malaria in infancy, neither LBW nor maternal peripheral and PM infections at delivery were used as covariates in the multivariate Cox proportional models. The effect of the interventions on the incidence of clinical malaria episodes and NMFs was investigated using Poisson regression or negative binomial models depending on the goodness-of-fit tests, with results expressed as incidence rate ratio (IRR) with 95% confidence interval (CI). Linear regression analysis was used for log-transformed parasite densities and logistic regression models for P. falciparum infection excluding censored infants. Variables with a P value <.1 in univariate analyses were included in multivariable analyses. A P value <.05 was considered to be statistically significant. The definitions of terms and the different categories of prenatal malaria exposure used in the present study are shown in Supplementary Table 1 .
RESULTS
Study Population
The flow chart of the birth cohort study is shown in Figure 1 . Of the 761 infants (from 752 mothers) enrolled in the study, 669
Pregnant women enrolled into COSMIC trial 1800
Pregnant women enrolled into birth-cohort study 752 [14] were recruited into the study at birth and followed up until 12 months of age. Lost to follow-up are infants who did not complete the 12-month follow-up. They were considered as censored observations at the time of the last visit in survival analysis. Neonatal deaths and twins were excluded from the analysis. *Not included in the survival analysis. **Included in the survival analysis. Abbreviations: COSMIC, community-based screening and treatment of malaria in pregnancy; a cluster randomized trial; CSST/IPTp-SP, community-based scheduled screening and treatment of malaria in combination with intermittent preventive treatment with sulfadoxine-pyrimethamine; ICF, informed consent form; IPTp-SP, intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine.
Newborns included 761
CSST/IPTp-SP
(88%) completed the 12-month follow-up. Of the remaining 92 infants, 41 were lost to follow-up, 38 had consent withdrawn mainly because of migration from the study area, and 13 died (7 neonatal deaths and 6 within 1-12 months). In total, 734 of the initial 761 infants were included in the survival analysis (367 in each COSMIC study arm). The infants excluded from the analysis were the 7 neonates who died before 4 weeks of age and the 20 live twins, although they completed follow-up. The cross-sectional surveys conducted at 3, 6, 9, and 12 months of age included 678 (92.4%), 631 (86%), 587 (80%), and 638 (86.9%) infants, respectively. Table 1 presents the characteristics of the mothers and infants as a whole and by MiP intervention group. The baseline maternal and infant demographic and parasitological characteristics were similar between the participants in the CSST/IPTp-SP and standard IPTp-SP arms.
Malaria Infections
Overall incidence of clinical malaria in the study population was 1.03 episodes per child-year (a total of 717 cases over 8335.18 months at risk), and the median survival time from birth to the first clinical malaria episode was 9.9 months. 
Effect of CSST/IPTp-SP Strategy on Time to First Clinical Malaria Episode
Although time to first clinical malaria episode was not significantly different between the 2 study arms in univariate and multivariate analyses (Table 2) , birth season was found to interact and significantly modify the effect of CSST/IPTp-SP on time to first clinical malaria episodes. We observed that infants born to mothers in the CSST/IPTp-SP arm during malaria 
. We investigated whether the observed effect of CSST/IPTp-SP could be explained by differences in prenatal malaria exposure. Table 3 shows that the increased risk of time to first clinical malaria episode was associated with peripheral infection during pregnancy and past PM (P = .009 and P = .020, respectively) but not with active PM (P = .177), after adjusting by gravidity, birth season, and LBW. Thus, the effect of CSST/IPTp-SP on time to first clinical malaria episode was more likely to be attributable to the impact on malaria infection during pregnancy rather than to active PM.
The two COSMIC study arms had a similar effect on infant parasite density during the first clinical malaria episode (6557. Table 2 ). Table 4 shows results of the analysis of the effect of the CSST/ IPTp-SP strategy on the incidence of clinical malaria episodes, including repeated malaria attacks per infant during the first year of life. We found no significant differences between CSST/ IPTp-SP and IPTp-SP after adjusting for birth season (adjusted IRR, 0.95 [95% CI, .82-1.10]; P = .459). Moreover, no significant differences were observed in the stratified analysis by birth season (high-transmission season: IRR, 0.99 [95% CI, .82-1.20], P = .941; low-transmission season IRR, 0.91 [95% CI, .72-1.14], P = .409).
Effect of CSST/IPTp-SP Strategy on the Incidence of Clinical Malaria Episodes
Effect of CSST/IPTp-SP Strategy on P. falciparum Infections
In total, 553 of 690 infants (80.14%) experienced at least 1 symptomatic or asymptomatic infection during the first year of life. The odds of experiencing a P. falciparum infection in infants born to mothers in the CSST/IPTp-SP group was not significantly different from that of children born to mothers in the IPTp-SP group, even after controlling for gravidity (adjusted odds ratio, 1.20 [95% CI, .82-1.74]; P = .348; Supplementary Table 3 ). There were also no statistical differences between the groups in terms of the proportions of asymptomatic infections in infants, regardless of the time of screening (Supplementary Table 4 ).
Effect of CSST/IPTp-SP Strategy on the Incidence of NMFs
A total of 805 NMFs episodes (incidence, 1.16 per child-year) were recorded in the 734 infants analyzed during their first year of life. Table 5 presents the stratified analysis by birth season Table 5 ).
DISCUSSION
In this prospective birth cohort study we found that, compared with the standard IPTp-SP strategy, CSST/IPTp-SP significantly increased time to first clinical malaria episode in infants born during malaria low-transmission season, and protected Abbreviations: CI, confidence interval; HR, hazard ratio; ITN, insecticide-treated net; LBW, low birth weight; PM, placental malaria..
a Adjusted by variables that showed a P value <.1 in univariate analyses.
against the occurrence of NMFs in those born during malaria high-transmission season. Due to the transmission seasonality of malaria and NMFs in Burkina Faso, CSST/IPTp-SP strategy appears to have different impact in women who had the main course of their pregnancy during malaria high-transmission season (and most probably gave birth during malaria low-transmission season) compared to those who were pregnant during malaria low-transmission season (and most probably gave birth during malaria high-transmission season). Our findings show, for the first time, that MiP preventive treatments may provide protection against malaria in infants during the first year of life, in addition to the known protection against adverse pregnancy outcomes. New MiP strategies should thus be evaluated not only for the protective effect on pregnancy outcomes but also the potential additional longterm benefits in infants. To our knowledge, only 1 study has compared the incidence of malaria in infants born to mothers who received either IPTp-SP or screening and treatment with RDT and artemether-lumefantrine during antenatal care visits, without IPTp-SP [13] . The authors found no differences in the risk of clinical malaria episodes during early life and observed that the 2 interventions had similar performance in preventing PM [13] . In comparison, the strategy of combining a CSST with the standard IPTp-SP increases the chances of clearing parasite infections when the protective efficacy of IPTp-SP is waned, thus reducing the risk of long-term parasite carriage during pregnancy. Indeed, thanks to the enhanced screening, the proportion of malaria infections detected by RDTs among women in the CSST/IPTp-SP arm was significantly higher than that among women in the routine IPTp-SP arm (Table 1) .
Remarkably, the impact of the CSST/IPTp-SP strategy on the risk of malaria in infancy was evident in infants born to women who had the main course of their pregnancy during malaria high-transmission season (and thus born during Abbreviations: CI, confidence interval; CSST/IPTp-SP, community-based scheduled screening and treatment of malaria in combination with intermittent preventive treatment with sulfadoxine-pyrimethamine; IPTp-SP, intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine; IRR, incidence rate ratio; ITN, insecticide-treated net; MiP, malaria in pregnancy.
a Adjusted by variables that showed a P value < .1 in univariate analysis. Abbreviations: CI, confidence interval; CSST/IPTp-SP, community-based scheduled screening and treatment of malaria in combination with intermittent preventive treatment with sulfadoxine-pyrimethamine; IPTp-SP, intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine; IRR, incidence rate ratio.
a Adjusted by gravidity or by birth season.
low-transmission season), whereas the 2 interventions performed similarly when the main course of pregnancy was during the low-transmission season. Therefore, we hypothesized that this effect of CSST/IPTp-SP is attributable to the additional reduction in parasite exposure that was not prevented by the standard IPTp-SP owing to the fact that maternal peripheral infections were associated with an increased risk of malaria in infants ( Table 3 ). The observation that past PM and peripheral infections during pregnancy, but not active PM, were associated with a risk of clinical malaria suggests that preventing infections at an early stage of pregnancy may have a critical effect on future infant susceptibility. Most studies to date have focused in looking at the association between PM and malaria risk, probably thus missing the overall effect of preventing all infections [3] [4] [5] [6] [7] [8] . Our findings are supported by a recent study that showed that the timing of prenatal malaria exposure had a pivotal role on the polarization of the fetal immune responses [19] . In this context, the study that we are currently conducting on the relationships between types of prenatal malaria exposure, innate immune responses at birth, and the subsequent risk of malaria in early infancy will provide further understanding on how maternal infections modulate newborns' immune responses and affect risk of malaria during the first year of life. CSST/IPTp-SP significantly increased time from birth to the first clinical malaria episode compared with the standard IPTp-SP in infants born during the low-transmission season; however, this effect did not translate into a significant reduction of malaria incidence in the same group. Although the difference was nonsignificant, the overall clinical malaria incidence was also reduced in these infants, suggesting that a MiP intervention with a stronger effect size on time to first infection would further reduce malaria incidence in infancy. In this study, the observed effect of the CSST/IPTp-SP intervention may have been limited by the sensitivity of the RDT used during screenings (limit of detection of approximately 200 parasites/µL) [20] . It is thus reasonable to assume that the lack of effect observed in infants born to mothers who were mostly pregnant during the low-transmission season might be due to the reduction of transmission intensity during this time and to the possibility that RDTs might have missed a considerable proportion of low-density infections [21] . We are tempted to speculate that the effect of the CSST/IPTp-SP intervention could be increased with the use of high-sensitivity diagnostic tools capable of detecting low-density infections. In this regard, high-sensitivity RDTs currently used in field testing [22] and molecular strategies such as loop-mediated isothermal amplification (LAMP) [23] are promising tools to improve screening strategies.
It is noteworthy that the CSST/IPTp-SP intervention was also associated with a reduced incidence of NMFs during the first year of life in infants born during malaria high-transmission season but not in those born during malaria low-transmission season. Therefore, it is unlikely that the same mechanism underlies the susceptibility to NMF as this protection [24] was independent of PM, even after exploring the association with different categories of prenatal malaria exposure. Nevertheless, several studies have reported modulation of the fetal immune system by malaria infections during pregnancy [19, 25, 26] . In addition to malaria-specific immune responses, these modifications may also affect specific immunity to other pathogens responsible for NMFs [27, 28] , such as those caused by bloodstream infections, gastrointestinal infections, acute respiratory infections, urinary tract infections, and arbovirus infections [29, 30] .
Moreover, the CSST/IPT-SP intervention was found to interact with gravidity to significantly protect infants born to multigravid women but not these born to either secundigravid (nonsignificant protection) or primigravid women (nonsignificant increased risk). These findings suggest that, through the modification of prenatal malaria exposure (which may differ depending on gravidity), the CSST/IPTp-SP intervention alters or primes the development of fetal immune system affecting immunity to pathogens that are responsible for NMFs in early infancy. To further gain understanding of how MiP preventive interventions can modulate the immune system to impact infant susceptibility to NMFs, new studies should include diagnosis of NMFs.
CONCLUSIONS
In this study we have shown that, compared with standard IPTp-SP, CSST/IPTp-SP significantly decreases the risk of experiencing a first clinical malaria episode and also interacts with birth season and gravidity to reduce the incidence of NMFs during the first year of life. Altogether, our findings suggest that MiP preventive strategies which effectively reduce exposure to malaria parasites during pregnancy could provide additional protection against both malaria and NMFs in early infancy and, therefore, have long-term benefits in infants.
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